Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04135937 · ClinicalTrials.gov registry record · Phase 4
Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT04135937: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT04135937 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04135937, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
Smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV). Smoking cessation interventions for this population are lacking. The primary aim of this project is to explore smoking cessation treatment preferences among Veteran smokers living with HIV. The study team will refine the design and content of a smoking cessation treatment for Veteran smokers living with HIV. The intervention uses mobile health and telehealth technology to personalize smoking cessation counseling and medications and provide relapse prevention text messaging.
Interventions
- DRUG Varenicline
- BEHAVIORAL Cognitive Behavioral Therapy
- DRUG Bupropion
- DRUG Nicotine Replacement Therapy
- BEHAVIORAL Relapse Prevention Text Messaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2021-11-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04135937
The ClinicalTrials.gov registry entry for NCT04135937 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Varenicline is the first listed.
NCT04135937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04135937 about?
NCT04135937 is a clinical study titled "Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)". Smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV). Smoking cessation interventions for this population are lacking. The primary aim of this project is to explore smoking cessation treatment preferences among Veter...
What is the current status of trial NCT04135937?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2019-11-18. Estimated completion is 2021-11-10.
What interventions are being tested in trial NCT04135937?
The interventions under investigation include: Varenicline (DRUG), Cognitive Behavioral Therapy (BEHAVIORAL), Bupropion (DRUG), Nicotine Replacement Therapy (DRUG), Relapse Prevention Text Messaging (BEHAVIORAL).
Who is sponsoring clinical trial NCT04135937?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.